- Email: [email protected]
Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
abstracts
Annals of Oncology
984P
Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Background: Despite improvements in diagnosis and aggressive chemotherapy treatment, a proportion of young patients are still dying from germ cell cancer (GCC). We aim to identify additional prognostic factors that help to select patients that might benefit from new treatment strategies. Anaemia is prognostic in several tumours. Thus, our objective was to address the prognostic significance of anaemia in disseminated testicular GCC. Methods: A multicentre, observational, retrospective study of patients with disseminated testicular GCC receiving first-line platinum-containing chemotherapy between 2000-2014, pooled from the Spanish Germ-Cell Cancer Group registry and another 3 tertiary hospitals. All patients with haemoglobin level available at diagnosis were selected for the analysis. We used the Cox-proportional hazard model to identify prognostic factors. Results: 665 consecutive patients from 18 centres were included for analysis. The patient distribution according to the International Germ Cell Cancer Collaboration Group (IGCCCG) classification was: 427, 125 and 113 patients for good, intermediate and poor risk categories, respectively. Hb < 10 g/dL (anaemia) was observed in 22 (3%) patients and was associated with worse PFS (p < 0.001) and OS (p < 0.001). Anaemia was more frequently observed in the poor prognostic group (good risk: 1.4%, intermediate risk: 2.6% and poor risk: 13.1%, p < 0.001), and in the multivariate analysis we observed an interaction between anaemia and the IGCCCG classification. We then analysed the prognostic significance of anaemia in each risk group. Anaemia remained as an independent prognostic factor in the poor risk group both for PFS (HR ¼ 2.18, 95%CI: 1.02-4.64; p ¼ 0.04) and for OS (HR ¼ 3.29, 95%CI: 1.42-7.65; p ¼ 0.006). No effect was observed in the good and intermediate risk group, although statistical power was limited in these subgroups due to the low number of patients with anaemia and events. Conclusions: In our series, Hb < 10 g/dL at diagnosis was an independent prognostic factor in poor risk disseminated testicular GCC. Future collaborative studies in order to validate these finding in an independent cohort are needed. Legal entity responsible for the study: The Spanish Germ Cell Cancer Group (SGCCG). Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Volume 30 | Supplement 5 | October 2019
doi:10.1093/annonc/mdz249 | v399
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz249.080/5577007 by guest on 24 October 2019
E. Garcia Torralba1, D. Castellano Gauna2, N. Sobrevilla3, J. Guma4, M.I. Luengo5, noz7, B. Mellado8, A. Saenz9, C. Valverde10, A. Fernandez11, J. Aparicio6, A. Sanchez-Mu~ M. Margeli12, I. Duran13, S. Fernandez14, J. Sastre15, S. Ros16, P. Maroto17, J.L. Aguilar18, X. Garcia del Muro19, E. Gonzalez Billalabeitia20 1 Servicio de Hematologıa y Oncologıa Me´dica, Hospital Universitario Morales Meseguer, Murcia, Spain, 2Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain, 3Medical Oncology Department, Instituto Nacional de Cancerologıa, Mexico City, Mexico, 4Medical Oncology Department, Hospital Universitario Sant Joan, Reus, Spain, 5Medical Oncology Department, Hospital General Universitario Santa Lucıa, Cartagena, Spain, 6Medical Oncology Department, Hospital Universitario y Polite´cnico La Fe, Valencia, Spain, 7Medical Oncology Department, Hospital Universitario Virgen de la Victoria, M alaga, Spain, 8Medical Oncology Department, Hospital Clınic de Barcelona, Barcelona, Spain, 9Medical Oncology Department, Hospital Clınico Universitario Lozano Blesa, Zaragoza, Spain, 10Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain, 11Medical Oncology Department, Complejo Hospitalario Universitario de Albacete, Albacete, a d’Oncologia-Hospital Germans Trias i Pujol, Spain, 12Urology Oncology, Institut Catal Badalona, Spain, 13Urology Oncology, Hospital Universitario Virgen del Rocio, Seville, 14 Spain, Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain, 15Medical Oncology Department, Hospital Clınico San Carlos, Madrid, Spain, 16Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 17 Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 18 Urological Oncology Department, Instituto Nacional de Cancerologıa, Mexico City, Mexico, 19Urology Oncology, ICO - Institut Catala d’Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, Spain, 20Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain
Annals of Oncology
984P
Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Background: Despite improvements in diagnosis and aggressive chemotherapy treatment, a proportion of young patients are still dying from germ cell cancer (GCC). We aim to identify additional prognostic factors that help to select patients that might benefit from new treatment strategies. Anaemia is prognostic in several tumours. Thus, our objective was to address the prognostic significance of anaemia in disseminated testicular GCC. Methods: A multicentre, observational, retrospective study of patients with disseminated testicular GCC receiving first-line platinum-containing chemotherapy between 2000-2014, pooled from the Spanish Germ-Cell Cancer Group registry and another 3 tertiary hospitals. All patients with haemoglobin level available at diagnosis were selected for the analysis. We used the Cox-proportional hazard model to identify prognostic factors. Results: 665 consecutive patients from 18 centres were included for analysis. The patient distribution according to the International Germ Cell Cancer Collaboration Group (IGCCCG) classification was: 427, 125 and 113 patients for good, intermediate and poor risk categories, respectively. Hb < 10 g/dL (anaemia) was observed in 22 (3%) patients and was associated with worse PFS (p < 0.001) and OS (p < 0.001). Anaemia was more frequently observed in the poor prognostic group (good risk: 1.4%, intermediate risk: 2.6% and poor risk: 13.1%, p < 0.001), and in the multivariate analysis we observed an interaction between anaemia and the IGCCCG classification. We then analysed the prognostic significance of anaemia in each risk group. Anaemia remained as an independent prognostic factor in the poor risk group both for PFS (HR ¼ 2.18, 95%CI: 1.02-4.64; p ¼ 0.04) and for OS (HR ¼ 3.29, 95%CI: 1.42-7.65; p ¼ 0.006). No effect was observed in the good and intermediate risk group, although statistical power was limited in these subgroups due to the low number of patients with anaemia and events. Conclusions: In our series, Hb < 10 g/dL at diagnosis was an independent prognostic factor in poor risk disseminated testicular GCC. Future collaborative studies in order to validate these finding in an independent cohort are needed. Legal entity responsible for the study: The Spanish Germ Cell Cancer Group (SGCCG). Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Volume 30 | Supplement 5 | October 2019
doi:10.1093/annonc/mdz249 | v399
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz249.080/5577007 by guest on 24 October 2019
E. Garcia Torralba1, D. Castellano Gauna2, N. Sobrevilla3, J. Guma4, M.I. Luengo5, noz7, B. Mellado8, A. Saenz9, C. Valverde10, A. Fernandez11, J. Aparicio6, A. Sanchez-Mu~ M. Margeli12, I. Duran13, S. Fernandez14, J. Sastre15, S. Ros16, P. Maroto17, J.L. Aguilar18, X. Garcia del Muro19, E. Gonzalez Billalabeitia20 1 Servicio de Hematologıa y Oncologıa Me´dica, Hospital Universitario Morales Meseguer, Murcia, Spain, 2Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain, 3Medical Oncology Department, Instituto Nacional de Cancerologıa, Mexico City, Mexico, 4Medical Oncology Department, Hospital Universitario Sant Joan, Reus, Spain, 5Medical Oncology Department, Hospital General Universitario Santa Lucıa, Cartagena, Spain, 6Medical Oncology Department, Hospital Universitario y Polite´cnico La Fe, Valencia, Spain, 7Medical Oncology Department, Hospital Universitario Virgen de la Victoria, M alaga, Spain, 8Medical Oncology Department, Hospital Clınic de Barcelona, Barcelona, Spain, 9Medical Oncology Department, Hospital Clınico Universitario Lozano Blesa, Zaragoza, Spain, 10Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona, Spain, 11Medical Oncology Department, Complejo Hospitalario Universitario de Albacete, Albacete, a d’Oncologia-Hospital Germans Trias i Pujol, Spain, 12Urology Oncology, Institut Catal Badalona, Spain, 13Urology Oncology, Hospital Universitario Virgen del Rocio, Seville, 14 Spain, Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain, 15Medical Oncology Department, Hospital Clınico San Carlos, Madrid, Spain, 16Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 17 Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 18 Urological Oncology Department, Instituto Nacional de Cancerologıa, Mexico City, Mexico, 19Urology Oncology, ICO - Institut Catala d’Oncologia Hospital Duran i Reynals, Hospitalet de Llobregat, Spain, 20Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain